Boule Diagnostics AB (OSTO:BOUL) ROCE % : 11.51% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Boule Diagnostics AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Boule Diagnostics AB's annualized ROCE % for the quarter that ended in Mar. 2024 was 11.51%.

Boule Diagnostics AB ROCE % Historical Data

The historical data trend for Boule Diagnostics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boule Diagnostics AB ROCE % Chart

Boule Diagnostics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

14.66

-12.08

9.95

6.67

7.45

Boule Diagnostics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															9.04	6.26	6.25	7.90	11.51

Boule Diagnostics AB ROCE % Calculation

Boule Diagnostics AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	41.364	/	( ( (759.964 - 201.034)	+	(755.105 - 202.999) )	/ 2 )
	=	41.364	/	( (558.93	+	552.106)	/ 2 )
	=	41.364	/	555.518
	=	7.45 %

Boule Diagnostics AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	65.2	/	( ( (755.105 - 202.999)	+	(797.4 - 216.3) )	/ 2 )
	=	65.2	/	( ( 552.106	+	581.1 )	/ 2 )
	=	65.2	/	566.603
	=	11.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Boule Diagnostics AB (OSTO:BOUL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Boule Diagnostics AB ROCE % Related Terms

Thank you for viewing the detailed overview of Boule Diagnostics AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Boule Diagnostics AB (OSTO:BOUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boule Diagnostics AB (OSTO:BOUL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Domnarvsgatan 4, Spanga, SWE, SE-163 53

Website

https://www.boule.com

Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The firm focuses on the decentralized market segment. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. Through its subsidiaries, the Group operates in Sweden, USA, and China.

Boule Diagnostics AB (OSTO:BOUL) Headlines

No Headlines